Feb 9, 2026 04:01PM
Jan 9, 2026 03:09AM
Jan 8, 2026 07:07AM
Jan 8, 2026 07:00AM
Nov 17, 2025 04:01PM
Nov 14, 2025 02:39AM
Sep 30, 2025 04:20AM Enanta Pharmaceuticals (ENTA) PT Raised to $9 at Leerink Partners
Sep 29, 2025 06:30AM
Sep 29, 2025 06:30AM
Aug 11, 2025 04:02PM
Aug 6, 2025 07:56PM
Jun 11, 2025 12:34PM
Jun 11, 2025 12:34PM
May 12, 2025 04:01PM Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025
Feb 10, 2025 04:01PM
Dec 9, 2024 06:32AM
Dec 9, 2024 06:30AM
Dec 6, 2024 05:00PM
Nov 25, 2024 04:01PM
Sep 26, 2024 06:02AM
Sep 26, 2024 06:00AM Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
Jan 4, 2024 07:00AM
Nov 20, 2023 04:01PM
Aug 7, 2023 04:01PM
Jun 20, 2023 07:00AM
Jun 20, 2023 07:00AM
Apr 6, 2023 07:01AM
Apr 6, 2023 07:00AM Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
Jan 6, 2023 07:00AM
Nov 21, 2022 04:02PM
Nov 9, 2022 07:00AM
Oct 3, 2022 07:00AM
Aug 8, 2022 04:03PM
Aug 8, 2022 04:00PM
Aug 8, 2022 04:00PM Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer
Jul 29, 2022 07:00AM
Jul 29, 2022 07:00AM
May 18, 2022 04:01PM
May 18, 2022 04:01PM
May 9, 2022 04:01PM
Mar 29, 2022 07:00AM
Mar 29, 2022 07:00AM Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19
Feb 17, 2022 07:03AM
Feb 17, 2022 07:00AM
Feb 8, 2022 04:01PM
Jan 6, 2022 07:00AM
Oct 4, 2021 07:06AM
Oct 4, 2021 07:00AM
Jan 8, 2021 07:06AM Enanta Pharma (ENTA) to Provide Updates on its Research and Development Programs and Outlook for 2021 at the 39th Annual J.P. Morgan Healthcare Conference
Jan 8, 2021 07:01AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All